INTRODUCTION: Crohn's disease (CD), a subtype of inflammatory bowel disease, is a growing health concern. In this study, we examined the influence of biologics on prescription trends and steroid dependency. METHODS: This retrospective longitudinal analysis of insurance coverage spanned at least 1 year before and 1 year after the inflammatory bowel disease diagnosis and enrolled 4476 patients with CD. The study period was divided into the pre-biologics and post-biologics eras according to the date when the first CD-related prescription was issued. We examined prescription patterns, steroid dependency rates, and concurrent use of immunomodulators or biologics. RESULTS: The CD incidence ranged from 1.6 to 1.3 cases per 100,000 patients between 2006 and 2018. During the pre-biologics era, the initial medications primarily comprised steroids (76.2%), followed by 5-aminosalicylic acid (44%) and immunomodulators (5.8%). During the post-biologics era, the initial prescription rates of steroids (69.8%) and 5-aminosalicylic acid (60.5%) remained high, and the Immunomodulators prescription rate increased to 14.7%. Steroid dependency was observed in 25.5 of 1000 and 22.1 of 1000 person-years during the pre-biologics and post-biologics eras, respectively. In the pre-biologics era, 6.1% of patients with steroid dependence received concurrent treatment with immunomodulators within the first 6 months. In the post-biologics era, this percentage increased to 24.2%, with some patients receiving immunomodulators or biologics. CONCLUSIONS: The incidence rate in Taiwan showed a stable trend annually. Biologics approval and policy implementation resulted in increased immunomodulator use and decreased steroid dependency.